Aim Immunotech Inc. (AIM)
XASE:AIM
Want to see AIM full AI Analyst Report?
AIM Stock Chart & Stats
$1.25
>-$0.01(-4.03%)
At close: 4:00 PM EST
$1.25
>-$0.01(-4.03%)
Day’s Range― - ―
52-Week Range$0.21 - $20.33
Previous CloseN/A
Volume272.06K
Average Volume (3M)55.35M
Market Cap
$5.91M
Enterprise Value$145.96K
Total Cash (Recent Filing)$5.88M
Total Debt (Recent Filing)$4.57M
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Aug 18, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.82
Shares Outstanding14,563,515
10 Day Avg. Volume53,446,745
30 Day Avg. Volume55,346,877
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.19
Price to Sales (P/S)20.78
P/FCF Ratio-0.16
Enterprise Value/Market Cap0.02
Enterprise Value/Revenue1.55
Enterprise Value/Gross Profit-1.17
Enterprise Value/Ebitda-0.01
Forecast
1Y Price Target
$5.25Price Target Upside320.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.32
Revenue Forecast (FY)$100.00K
Bulls Say, Bears Say
Bulls Say
Listing Compliance And Capital RaiseRestoring NYSE American compliance via May–June financings that generated material proceeds reduces delisting risk and secures funding for clinical programs. This durable improvement in capital base supports ongoing trial timelines and regulatory work, improving operational continuity over the next several months.
Clinical Progress: Ampligen In OncologyClinical signals, KOL endorsement and a partnership-stage Phase 2 trial with a major oncology agent represent structural advancement. Positive survival signals and peer-reviewed data strengthen the program's scientific credibility and create a clearer path to confirmatory studies or partnering/licensing opportunities over the medium term.
Low Debt / Modest LeverageVery limited reported debt reduces interest and covenant pressure, preserving flexibility to prioritize R&D and clinical manufacturing. Modest leverage lowers near-term solvency risk and gives management more optionality in choosing dilutive equity or strategic partnerships to fund development without immediate debt-service strain.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow at multi‑million annualized levels means the business must continually access external funding to maintain trials and operations. Without milestone-driven non-dilutive inflows or a material commercial revenue source, cash burn materially elevates dilution and execution risk over coming quarters.
Minimal Revenue & Negative ProfitabilityWith negligible commercial revenue and persistent negative margins, the company remains a development-stage biotech dependent on clinical success or licensing to reach sustainable earnings. This structural lack of revenues limits internal funding capacity and extends reliance on external capital until product approval or partnerships occur.
High Dilution Risk From Repeated FinancingsFrequent use of warrant inducements, registered direct offerings and expanded ATM capacity indicates structural dependence on equity-linked funding. That recurring dilution risk, combined with past swings into negative equity, can erode existing shareholder value and complicate long-term returns absent decisive clinical or commercial milestones.
AIM ImmunoTech News
AIM FAQ
What was Aim Immunotech Inc.’s price range in the past 12 months?
Aim Immunotech Inc. lowest stock price was $0.21 and its highest was $20.33 in the past 12 months.
What is Aim Immunotech Inc.’s market cap?
Aim Immunotech Inc.’s market cap is $5.91M.
When is Aim Immunotech Inc.’s upcoming earnings report date?
Aim Immunotech Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 63 days.
How were Aim Immunotech Inc.’s earnings last quarter?
Currently, no data Available
Is Aim Immunotech Inc. overvalued?
According to Wall Street analysts Aim Immunotech Inc.’s price is currently Undervalued.
Does Aim Immunotech Inc. pay dividends?
Aim Immunotech Inc. pays a N/A dividend of $0.272 which represents an annual dividend yield of N/A. See more information on Aim Immunotech Inc. dividends here
What is Aim Immunotech Inc.’s EPS estimate?
Aim Immunotech Inc.’s EPS estimate is -0.17.
How many shares outstanding does Aim Immunotech Inc. have?
Aim Immunotech Inc. has 14,563,515 shares outstanding.
What happened to Aim Immunotech Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Aim Immunotech Inc.?
Currently, no hedge funds are holding shares in AIM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aim Immunotech Inc.
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.
AIM Stock 12 Month Forecast
Average Price Target
$5.25
▲(320.00% Upside)
Technical Analysis
Ownership Overview
0.89% Insiders
0.20% Mutual Funds
<0.01% Other Institutional Investors
98.91% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---